Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
- The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region
- Significantly enhances Hansa’s financial position, ensuring a robust U.S. launch and provides path to profitability, subject to US approval
- SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Lund, Sweden, May 19, 2026. Hansa Biopharma AB (“Hansa” or “the Company”) (Nasdaq Stockholm: HNSA) and SERB S.A. (“SERB”) today announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.
